$OKLO

Cochran Caroline sold $995K of OKLO

Cochran Caroline (Co-Founder, COO) sold 14,814 shares of Oklo Inc. (OKLO) at $67.15 ($0.99M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cochran Caroline
Published Jun 2, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

This provides a dated, priced insider transaction datapoint that may influence short-term sentiment, but the pre-arranged nature generally limits inference about near-term fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a major repricing absent other catalysts.

03

What to watch

The filing does not indicate whether additional sales occurred concurrently, nor does it reveal tax/financing motives; also, the sale is small relative to typical float for high-volatility growth names.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today; sale executed 2026-06-01

Background

The article is an SEC Form 4 disclosure of an insider’s sale of Oklo shares, including that it was executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder/COO and 10% owner sold 14,814 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low-to-moderate near-term downside bias possible, but magnitude likely limited by 10b5-1 context.

Evidence & confidence

The filing provides a concrete sale size and price, but explicitly states it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider transaction with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be routine liquidity events; the market may overreact to the headline without implying deterioration.

Key entities

  • Oklo Inc.

    Subject of the insider transaction disclosure (Form 4) for shares sold by a co-founder/COO and 10% owner.

  • Cochran Caroline

    Oklo co-founder, COO, officer/director/10% owner who sold 14,814 shares at $67.15 under a 10b5-1 plan.

Related articles

$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

$OKLOMedAI 8/10

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.